We are live on ! Find out more
RGC icon

Regencell Bioscience

31 hedge funds and large institutions have $16.5M invested in Regencell Bioscience in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

82% more funds holding

Funds holding: 1731 (+14)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

43% more capital invested

Capital invested by funds: $11.5M → $16.5M (+$4.94M)

0.02% more ownership

Funds ownership: 0.11%0.13% (+0.02%)

37% less call options, than puts

Call options by funds: $1.74M | Put options by funds: $2.78M

Holders
31
Holders Change
+14
Holders Change %
+82.35%
% of All Funds
0.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
6
Reduced
4
Closed
4
Calls
$1.74M
Puts
$2.78M
Net Calls
-$1.04M
Net Calls Change
-$351K

RGC Hedge Fund Activity: Q1 2026 in Review

31 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2026, worth a combined $16.5M — up 43% from $11.5M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RGC positions and 4 closed out — a net gain of 14 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Marex Group, opening a new position worth an estimated $894K. The largest seller was XTX Topco, exiting entirely with an estimated $317K sold.

  • 31 institutional investors held Regencell Bioscience (RGC) as of Q1 2026, up from 17 in Q4 2025.
  • Funds reported $16.5M of Regencell Bioscience stock for Q1 2026, up 43% quarter-over-quarter.
  • 18 funds opened new Regencell Bioscience positions in Q1 2026 and 4 closed out, a net change of +14 holders.
  • The largest Regencell Bioscience buyer in Q1 2026 was Marex Group, an estimated $894K added.
  • The largest Regencell Bioscience seller in Q1 2026 was XTX Topco, an estimated $317K sold.

Based on aggregated 13F filings for Q1 2026.